Search Results - "Toschi, L"

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients by Cappuzzo, F., Jänne, P. A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., Zucali, P. A., Terracciano, L., Toschi, L., Roncalli, M., Destro, A., Incarbone, M., Alloisio, M., Santoro, A., Varella-Garcia, M.

“…Background: MET amplification has been detected in ∼20% of non-small-cell lung cancer patients (NSCLC) with epidermal growth factor receptor (EGFR) mutations…”
Get full text

The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art by Franceschini, D., De Rose, F., Cozzi, S., Franzese, C., Rossi, S., Finocchiaro, G., Toschi, L., Santoro, A., Scorsetti, M.

“…•Despite high efficacy, resistance to target therapies in NSCLC always occurs.•When occurrence is limited to few sites, local therapies can be…”
Get full text

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo by Chaturvedi, A, Herbst, L, Pusch, S, Klett, L, Goparaju, R, Stichel, D, Kaulfuss, S, Panknin, O, Zimmermann, K, Toschi, L, Neuhaus, R, Haegebarth, A, Rehwinkel, H, Hess-Stumpp, H, Bauser, M, Bochtler, T, Struys, E A, Sharma, A, Bakkali, A, Geffers, R, Araujo-Cruz, M M, Thol, F, Gabdoulline, R, Ganser, A, Ho, A D, von Deimling, A, Rippe, K, Heuser, M, Krämer, A

“…Neomorphic mutations in isocitrate dehydrogenase 1 ( IDH1 ) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead…”
Get full text

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients by Cappuzzo, F, Varella-Garcia, M, Finocchiaro, G, Skokan, M, Gajapathy, S, Carnaghi, C, Rimassa, L, Rossi, E, Ligorio, C, Di Tommaso, L, Holmes, A J, Toschi, L, Tallini, G, Destro, A, Roncalli, M, Santoro, A, Jänne, P A

“…The impact of KRAS mutations on cetuximab sensitivity in epidermal growth factor receptor fluorescence in situ hybridisation-positive ( EGFR FISH+) metastatic…”
Get full text

Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients by De Rose, F, Cozzi, L, Navarria, P, Ascolese, A.M, Clerici, E, Infante, M, Alloisio, M, Testori, A, Toschi, L, Finocchiaro, G, Santoro, A, Scorsetti, M

“…Abstract Aims The aim of this observational study was the evaluation of toxicity, local control and overall survival in non-small cell lung cancer (NSCLC)…”
Get full text

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients by Cappuzzo, F., Tallini, G., Finocchiaro, G., Wilson, R.S., Ligorio, C., Giordano, L., Toschi, L., Incarbone, M., Cavina, R., Terracciano, L., Roncalli, M., Alloisio, M., Varella-Garcia, M., Franklin, W.A., Santoro, A.

“…The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected…”
Get full text

Role of gemcitabine in cancer therapy by Toschi, L, Finocchiaro, G, Bartolini, S, Gioia, V, Cappuzzo, F

“…Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new cytotoxic agents. The drug has shown activity in a variety of solid…”
Get more information

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience by Luciani, A., Toschi, L., Fava, S., Cortinovis, D., Filipazzi, V., Tuzi, A., Marra, A., Rossi, S., Rossi, A., Blasi, M., Violati, M., Sala, L., Agustoni, F., Bidoli, P., Zonato, S., Ferrari, D.

Get full text

Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs by Franceschini, D., Rossi, S., Loi, M., Chiola, I., Piccoli, F., Lutman, F. R., Finocchiaro, G., Toschi, L., Santoro, A., Scorsetti, M.

“…Patients treated with third-generation EGFR TKIs will develop resistance to treatment at a certain point. Early detection of resistance occurrence could allow…”
Get full text

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients by CAPPUZZO, F, TOSCHI, L, FRANKLIN, W. A, CRINO, L, BUNN, P. A, HIRSCH, F. R, VARELLA-GARCIA, M, DOMENICHINI, I, BARTOLINI, S, CERESOLI, G. L, ROSSI, E, LUDOVINI, V, CANCELLIERI, A, MAGRINI, E, BEMIS, L

“…In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the…”
Get full text

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib by Cappuzzo, F., Toschi, L., Tallini, G., Ceresoli, G.L., Domenichini, I., Bartolini, S., Finocchiaro, G., Magrini, E., Metro, G., Cancellieri, A., Trisolini, R., Crino, L., Bunn, P.A., Santoro, A., Franklin, W.A., Varella-Garcia, M., Hirsch, F.R.

“…Background: The aim of the study was to assess whether loss of PTEN and expression of insulin-like growth factor receptor 1 (IGFR-1) could be responsible for…”
Get full text

EP-1168: Concurrent chemo-radiotherapy in locally advanced NSCLC: Toxicity and clinical outcomes using VMAT (rapid arc) by Ascolese, A, Navarria, P, De Rose, F, Villa, E, Toschi, L, Santoro, A, Stravato, A, Tomatis, S, Lobefalo, F, Scorsetti, M

Get full text

Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer by Toschi, L, Cappuzzo, F, Jänne, PA

Get full text

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC) by CAPPUZZO, F, BARTOLINI, S, CRINO, L, CERESOLI, G. L, TAMBERI, S, SPREAFICO, A, LOMBARDO, L, GREGORC, V, TOSCHI, L, CALANDRI, C, VILLA, E

“…The activity and toxicity profile of gefitinib in non-small cell lung cancer (NSCLC) patients aged 70 years or older has been only partially evaluated. The aim…”
Get full text

Changes in Cyclin/Proliferating Cell Nuclear Antigen Distribution during DNA Repair Synthesis by Toschi, Luisella, Bravo, Rodrigo

“…UV irradiation of quiescent human fibroblasts immediately triggers the appearance of the nuclear protein cyclin/proliferating cell nuclear antigen (PCNA) as…”
Get full text

Development of gemcitabine in non-small cell lung cancer: the Italian contribution by Metro, G., Cappuzzo, F., Finocchiaro, G., Toschi, L., Crinò, L.

“…Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new cytotoxic agents. The drug has shown activity in a variety of solid…”
Get full text

A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta by Gruenberg, B H, Schoenemeyer, A, Weiss, B, Toschi, L, Kunz, S, Wolk, K, Asadullah, K, Sabat, R

“…The cytokine receptor family type 2 (CRF2) comprises receptors for important immunomediators like interferons and interleukin-10 (IL-10). We identified a novel…”
Get full text

The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity by Zerial, M., Toschi, L., Ryseck, R. P., Schuermann, M., Müller, R., Bravo, R.

“…We have identified a gene, fos B, encoding a nuclear protein of 338 amino acids presenting a 70% homology with c‐fos, whose expression is activated during…”
Get full text

Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges by Cappuzzo, F, Toschi, L, Finocchiaro, G, Ligorio, C, Santoro, A

“…The epidermal growth factor receptor (EGFR) plays a key role in cancer development and progression in several human malignancies including non-small cell lung…”
Get full text

Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges by Cappuzzo, F, Toschi, L, Finocchiaro, G, Ligorio, C, Santoro, A

“…The epidermal growth factor receptor (EGFR) plays a key role in cancer development and progression in several human malignancies including non-small cell lung…”
Get full text